This Webull webinar provides an overview of eXoZymes’ AI-enhanced, cell-free biomanufacturing...

CCO at eXoZymes, Damien Perriman, interviewed at Nasdaq around our NCT project: "We’ve shown that...

Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter...

One of the biggest challenges of conventional technologies is the long timelines to advance...

The Catalyst Podcast by Igor Rafalovich is available here:...

Serial entrepreneur Michael Heltzen, CEO of eXoZymes, reveals how his NASDAQ-listed company is...

“Some of the challenges in SynBio, are the costs and the timelines. Timeline-wise, it takes a...